ESR1 and breast cancer: Prior results from the PeriOperative Endocrine Therapy for Individualised Care (POETIC)7 trial demonstrated that in ER+/HER2− BC, a simple biomarker, particularly dynamic change in Ki67 following short-duration preoperative AI can predict long-term survival outcome.